Background: Emerging evidence underscores the pivotal role of immunotherapies targeting B-cell maturation antigen (BCMA) in improving outcomes for multiple myeloma (MM) patients. With recent FDA approvals of CAR T-cell therapies for relapsed/refractory MM (RRMM) following multiple prior treatments, oncology clinicians urgently require up-to-date guidance to navigate evolving treatment options, combination strategies, and earlier-line interventions.

Purpose: This study evaluated whether digital, short-form, case-based education enhances clinicians' knowledge and competence in optimizing CAR T-cell therapy for RRMM.

Methods: US-based hematologists, hematologist-oncologists, nurse practitioners (NPs), and physician assistants (PAs) participated in an accredited live satellite symposium at ASH 2024 titled “A Step-by-Step Approach to CAR T-Cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management.” Following the live event, the symposium was adapted as a 15-minute on-demand e-learning program. Pre- and post-activity assessments measured learners' baseline knowledge and competence and the impact of the intervention. Data were analyzed in aggregate and by specialty.

Results: As of August 4, 2025, 4,591 clinicians completed the activity. Knowledge and competence improved significantly among hematologist-oncologists (26%), NPs (35%), and PAs (33%). Notable gains were seen in understanding the latest CAR T-cell regimens (12% increase), patient eligibility criteria (28% increase), and adverse event management (39% increase). Post-activity, learners reported increased confidence using CAR T-cell therapies, and 62% expressed interest in further education on emerging data for earlier-line treatments.

Conclusions: Digital, short-form, case-based CME effectively enhanced clinician knowledge and competence in CAR T-cell therapy for RRMM and identified ongoing educational gaps to inform future efforts.

This content is only available as a PDF.
2025
Sign in via your Institution